Goldman analsyt Jami Rubin said pressure to remove the black box label for TherapeuticsMD's Yuvexxy is growing as indicated by a letter from members of Congress to the FDA on October 11. The analyst said it represents a growing movement to increase accessibility for low-dose estrogen products that pose limited systemic risk. Rubin views TherapeuticsMD's recent share weakness as an attractive buying opportunity ahead of 2017 catalysts and upcoming data from the Phase III RELENISH study. The analyst rates TherapeuticsMD a Buy with a $10.50 price target.